PharmaCyte Historical Cash Flow
| PMCB Stock | USD 1.32 0.06 4.35% |
Analysis of PharmaCyte Biotech cash flow over time is an excellent tool to project PharmaCyte Biotech future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change To Inventory of 7.5 K or Begin Period Cash Flow of 82.2 M as it is a great indicator of PharmaCyte Biotech ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining PharmaCyte Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether PharmaCyte Biotech is a good buy for the upcoming year.
PharmaCyte |
About PharmaCyte Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in PharmaCyte balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which PharmaCyte's non-liquid assets can be easily converted into cash.
PharmaCyte Biotech Cash Flow Chart
Add Fundamental
Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from PharmaCyte Biotech's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into PharmaCyte Biotech current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.At present, PharmaCyte Biotech's Change In Working Capital is projected to increase significantly based on the last few years of reporting. The current year's Other Cashflows From Financing Activities is expected to grow to about 21.1 M, whereas Change In Cash is projected to grow to (19.5 K).
| 2024 | 2025 (projected) | Stock Based Compensation | 607.22 | 576.86 | Dividends Paid | 25.8M | 27.1M |
PharmaCyte Biotech cash flow statement Correlations
Click cells to compare fundamentals
PharmaCyte Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PharmaCyte Biotech cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 1.3M | 83.2M | (17.4M) | (17.9K) | (20.5K) | (19.5K) | |
| Free Cash Flow | (3.3M) | (4.1M) | (3.8M) | (2.2M) | (1.9M) | (2.0M) | |
| Change In Working Capital | (145.6K) | 9.0K | (297.2K) | 298.9K | 343.7K | 360.9K | |
| Other Cashflows From Financing Activities | (62.4K) | (50.8K) | 880.0 | 17.5M | 20.1M | 21.1M | |
| Total Cash From Operating Activities | (3.3M) | (4.1M) | (3.8M) | (2.2M) | (1.9M) | (2.0M) | |
| Net Income | (3.6M) | (4.2M) | (4.3M) | 333.8K | 300.4K | 315.4K | |
| Total Cash From Financing Activities | 4.6M | 87.3M | (13.6M) | (10.7M) | (12.3M) | (11.7M) | |
| Begin Period Cash Flow | 894.9K | 2.2M | 85.4M | 68.0M | 78.2M | 82.2M | |
| Other Non Cash Items | (4.9K) | 34.8K | 174.0K | (2.8M) | (2.5M) | (2.4M) | |
| End Period Cash Flow | 2.2M | 85.4M | 68.0M | 50.2M | 57.7M | 60.6M | |
| Change To Liabilities | (230.7K) | 64.0K | (13.6K) | 33.1K | 29.8K | 28.3K | |
| Stock Based Compensation | 370.8K | 78.0K | 645.4K | 674.69 | 607.22 | 576.86 | |
| Change To Operating Activities | 397.8K | 203.4K | (132.0K) | (24.1K) | (21.7K) | (20.6K) | |
| Change To Netincome | 1.0M | 1.2M | 366.0K | 112.8K | 101.5K | 96.4K | |
| Issuance Of Capital Stock | 4.7M | 87.4M | 0.0 | 33.7M | 38.7M | 24.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.